1832 Asset Management
AMPH icon

1832 Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

1832 Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$5.75M – 854
2023
Q2 		$5.75M Buy
+100,000
New +$4.43M 0.01% 379

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

1832 Asset Management's AMPH Position: Q3 2023 in Review

1832 Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2023, closing a stake of 100,000 shares — an estimated $5.75M sold.

1832 Asset Management first reported a position in AMPH in Q2 2023 and held it in 1 quarter. The position peaked at $5.75M in Q2 2023. 255 funds tracked by Wall St. Rank hold AMPH as of Q3 2023.

  • 1832 Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • 1832 Asset Management sold 100,000 Amphastar Pharmaceuticals shares in Q3 2023, an estimated $5.75M.
  • 1832 Asset Management first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • 1832 Asset Management's Amphastar Pharmaceuticals position peaked at $5.75M in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2023.

Based on 1832 Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.